Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.06 USD | -0.10% | +22.34% | +15.71% |
May. 30 | Barrington Research Downgrades SurModics to Market Perform From Outperform | MT |
May. 29 | Needham Downgrades SurModics to Hold From Buy | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company has insufficient levels of profitability.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.71% | 600M | C | ||
-7.16% | 178B | C+ | ||
-1.23% | 107B | C | ||
-4.86% | 67.04B | A | ||
-4.28% | 47.23B | B- | ||
+10.32% | 44.62B | B- | ||
+8.14% | 42.5B | B+ | ||
+15.53% | 25.22B | A- | ||
-5.88% | 24.14B | A- | ||
-5.38% | 23.69B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SRDX Stock
- Ratings Surmodics, Inc.